Buradasınız

Anasayfa » Content

Serebral palside botulinum toksininin yeri

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Cerebral Palsy is a disease that may show motion and posture disorders. One of the treatment methods of Botulinum toxin injection is a well tolerated, safe and effective procedure in the treatment of focal spasticity. In this article, cerebral palsy, structure of Botulinum toxin, then the technical issues including the selection of the patient suitable for treatment, the appropriate dosage, injection technique and aftercare have been discussed.
Bookmark/Search this post with
Abstract (Original Language): 
Serebral palsi hareket ve duruş bozuklukları ile seyreden bir hastalıktır. Serebral palsinin tedavi yöntemlerinden biri olan Botulinum toksin enjeksiyonu fokal spastisite tedavisinde etkin ve güvenilir bir yöntem olup, bu yazıda öncelikle serebral palsi, botulinum toksinin yapısı, tedaviye uygun hasta seçimi, doz, enjeksiyon tekniği, enjeksiyon sonrasındaki tedavi uygulamaları gibi dikkat edilmesi gereken teknik konular üzerinde yoğunlaşılacaktır.
FULL TEXT (PDF): 
PDF icon arastirmax-serebral-palside-botulinum-toksininin-yeri.pdf
  • 2
78-81
  • Turkish

REFERENCES

References: 

1. Badawi N, Watson L, Petterson B, et al. What constitute cerebral palsy. Dev Med Child Neurol 1998; 40:520¬7.
2. Graham H.K, Aoki K.R, Autti-Ramö I, Boyd R.N, Delgado M.R, Deborah J et all. Recommendation for the use of botulinum toxin type A in the management ofcerebral palsy. Gait and Posture 11, 2000, 67-79.
3. Dabney KW, Lipton GE, Miller F. Cerbral palsy. Curr OpinPediatr 1997; 9:81-8.
4. Cooper J, Majnemer A, Rosenblatt B, et al. The determination of sensory deficits in children with hemiplegiccerebralpalsy.JChildNeurol 1995; 10:300¬9.
5. Russman BS. Cerebral plasy. Current treatment options. Neurology2000;2:97-108.
6. Anonymous. Surveillance ofcerebral palsy in Europe (SSPE). Dev Med Child Neurol 2000; 42:816-24.
7.
Çi
l A, Aksoy M.C, Çeliker R. Serebral palsi tedavisinde botulinum toksini uygulamaları. Hacettepe Tıp Dergisi 2006; 37:43-48.
8. Boyd R.N, Graham H.K. Objective measurement of clinical findings in the use ofbotulinum toxin type A for the management ofchildren with cerabral palsy. EurJNeurol 1999;(Suppl.4):523-35.
9. Sathyamurthy V, Dasgupta BR. Separation, purification, partial characterization and comparison ofthe heavy and light chains ofbotulinum neurotoxin types A, B, and E. J Biol Chem 1985; 260:10461-6.
10. Jankovic J, Hallet M, eds. Therapy with botulinum
toxin. NewYork: Marcel Decker, 1994.
11. Moore P, ed. Handbook ofbotulinum toxin treatment. Oxford: Blackwell Science, 1995.
12. Carr LJ, Cosgrove AP, Gringrass P, et al. Position paper on the use ofbotulinum toxin in cerbral palsy. Arch Dis Child 1998; 79:271-3.
13. Mathiowetz V, Federman S, Wiemer D. Box and block test ofmanual dexterity: norms for 6-19year olds. Can JOccupTher 1985;52:241-5
14. Boyd R.N, Graham H.K. Botulinum toxin type A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 1997;4:S15-
22.
15. Delgado MR. The use ofbotulinum toxin type A in children with cerebral palsy: a retrospective study. Eur JNeurol 1999; 6(Suppl 4):11-8.
16. Bakheit AM, Severa S, Cosgrove A, et al. Safety profile ofbotulinum toxin (DYSPORT) in children with muscle spasticity. Dev Med ChildNeurol 2001;
43:234-8.
17. Corry I, Cosgrove A, Duffy C, McNeil S, Taylor T,Graham H. Botulinum toxin type A compared with stretching cast in the treatment of spastic equinus, a randomised prospective trial. J Pediatr Orthop 1998;18:304-11.

Thank you for copying data from http://www.arastirmax.com